Baidu
map

Cell Rep:科学家成功解析乳腺癌和卵巢癌风险相关蛋白复合体的精细结构

2017-01-16 佚名 生物谷

图片来源:medicalxpress.com 近日,来自英国弗朗西斯-克里克研究所(Francis Crick Institute)的研究人员通过研究描述了一种关键肿瘤抑制蛋白的分子结构,或为后期阐明该蛋白在细胞中的关键角色提供新的思路,相关研究刊登于国际杂志Cell Reports上。 BRCA1是一种人类机体基因,其能够产生名为BRCA1的肿瘤抑制蛋白,该基因突变会导致个体在一

图片来源:medicalxpress.com

近日,来自英国弗朗西斯-克里克研究所(Francis Crick Institute)的研究人员通过研究描述了一种关键肿瘤抑制蛋白的分子结构,或为后期阐明该蛋白在细胞中的关键角色提供新的思路,相关研究刊登于国际杂志Cell Reports上。

BRCA1是一种人类机体基因,其能够产生名为BRCA1的肿瘤抑制蛋白,该基因突变会导致个体在一生中出现65%-75%患乳腺癌的可能性;同时高风险乳腺癌的家族成员也都会进行BRCA1和相关的BRCA2基因的突变筛查。当然BRCA1蛋白在机体DNA修复过程中也扮演着保护性的角色,同时还能够帮助维持机体的遗传稳定性。

BRCA1基因的突变会导致相应蛋白产生不足,进而就会抑制DNA修复,从而导致机体出现遗传不稳定性的表现,而遗传不稳定就会增加个体患癌的可能性。BRCA1蛋白能够同三种蛋白复合物发生相互作用(BRCA1-A、BRCA1-B和BRCA1-C)。文章中研究者就描述了BRCA1-A蛋白的分子结构,同时深入阐明了其在细胞泛素降解过程中的关键角色,泛素降解能够参与对DNA修复机制的调节。

本文中,研究者利用一系列先进技术进行研究,比如电子显微镜检查术、质谱分析和生化分析;电子显微镜检查术能够用来解析蛋白复合物的整体形态,但其并不能针对性地检查单一份子组分的精确位点。将质谱法和生化分析法相结合就能够为科学家提供额外的信息来对组分的位点进行三角化测量。

长期以来,研究者们一直希望能够理解蛋白复合物的结构和功能,从而帮助开发BRCA1-A及相关复合物的新型抑制剂以供临床使用。研究者Steve Smerdon表示,在低分辨率下,蛋白复合物的结构仅仅是主要BRCA1复合体的结构一瞥而已;本文研究中我们所阐明的结构能够帮助我们阐明整体复合物架构如何能够稳定与泛素链的相互作用,更为重要的是,我们还阐明了如何与BRCA1相互作用才能够调节BRCA1的活性。

原始出处

Otto J.P. Kyrieleis5, Pauline B. McIntosh5, Sarah R. Webb, Lesley J. Calder, Janette Lloyd, Nisha A. Patel, Stephen R. Martin, Carol V. Robinson, Peter B. Rosenthal, Stephen J. Smerdon.Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex.Cell Rep.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797784, encodeId=50dc1e9778433, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Aug 03 23:45:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960000, encodeId=2cea1960000bc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 17 04:45:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672818, encodeId=cfe616e281887, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Thu Jan 19 04:45:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937727, encodeId=b58c193e727ed, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Apr 24 05:45:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061595, encodeId=2dd020615954f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 20 15:45:00 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869741, encodeId=bc4e1869e4163, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 10 21:45:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797784, encodeId=50dc1e9778433, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Aug 03 23:45:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960000, encodeId=2cea1960000bc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 17 04:45:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672818, encodeId=cfe616e281887, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Thu Jan 19 04:45:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937727, encodeId=b58c193e727ed, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Apr 24 05:45:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061595, encodeId=2dd020615954f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 20 15:45:00 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869741, encodeId=bc4e1869e4163, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 10 21:45:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-09-17 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797784, encodeId=50dc1e9778433, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Aug 03 23:45:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960000, encodeId=2cea1960000bc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 17 04:45:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672818, encodeId=cfe616e281887, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Thu Jan 19 04:45:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937727, encodeId=b58c193e727ed, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Apr 24 05:45:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061595, encodeId=2dd020615954f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 20 15:45:00 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869741, encodeId=bc4e1869e4163, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 10 21:45:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-01-19 hongbochen
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797784, encodeId=50dc1e9778433, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Aug 03 23:45:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960000, encodeId=2cea1960000bc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 17 04:45:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672818, encodeId=cfe616e281887, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Thu Jan 19 04:45:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937727, encodeId=b58c193e727ed, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Apr 24 05:45:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061595, encodeId=2dd020615954f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 20 15:45:00 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869741, encodeId=bc4e1869e4163, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 10 21:45:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-04-24 bioon1
  5. [GetPortalCommentsPageByObjectIdResponse(id=1797784, encodeId=50dc1e9778433, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Aug 03 23:45:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960000, encodeId=2cea1960000bc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 17 04:45:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672818, encodeId=cfe616e281887, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Thu Jan 19 04:45:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937727, encodeId=b58c193e727ed, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Apr 24 05:45:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061595, encodeId=2dd020615954f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 20 15:45:00 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869741, encodeId=bc4e1869e4163, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 10 21:45:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-02-20 sjq027
  6. [GetPortalCommentsPageByObjectIdResponse(id=1797784, encodeId=50dc1e9778433, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Aug 03 23:45:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960000, encodeId=2cea1960000bc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 17 04:45:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672818, encodeId=cfe616e281887, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Thu Jan 19 04:45:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937727, encodeId=b58c193e727ed, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Apr 24 05:45:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061595, encodeId=2dd020615954f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 20 15:45:00 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869741, encodeId=bc4e1869e4163, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 10 21:45:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]

相关资讯

阿斯汤加瑜伽是否对乳腺癌患者有好处?加拿大温莎大学将开展研究!

加拿大温莎大学(UOW)心理学教授Kendall Soucie、Josee Jarry及人体运动学教授Cheri McGowan将开展一项研究阿斯汤加瑜伽是否对对乳腺癌幸存者有益的实验,他们将从身体及心理上检测乳腺癌幸存者对阿斯汤加瑜伽产生的反应,据报道这项研究将获得温莎癌症中心基金会约70000美元的经费支持。他们将通过检测病人的自尊心是否增强、焦虑和抑郁是否减弱以及人际关系是否有改善来评估瑜

Cancer Res:一种新型癌症靶点有望被开发,展现治疗希望

美国南卡罗莱纳医科大学的研究人员最近设计了一种以抗体为基础的治疗方法能够靶向引起癌症的TGFβ。 TGFβ是一种细胞因子既可以调节细胞周期也可以被调节Τ细胞(Treg)当作一种信号用以告诉免疫细胞不要攻击正常细胞。TGFβ也是一个得到广泛研究的癌症细胞因子,恶性肿瘤会释放大量TGFβ帮助癌细胞快速分裂同时借助Treg抑制免疫细胞对癌细胞的杀伤。但是由于正常细胞不能缺少TGFβ,因此很难设

JCO:乳腺癌预防的早期中断因素有哪些?(MAP.3试验)

芳香化酶抑制剂已被确认为是乳腺癌患者化学预防的干预措施。然而,其依从性差仍然是一个重大的挑战。近期发表在JCO期刊上的一项研究探讨了其依从性较差的相关因素,以下是研究的主要内容:研究人员在加拿大国立癌症研究所(NCIC)的乳腺癌预防试验3(MAP.3)中调查了绝经期特异性生活质量的恶化、基线参与者的特征与早期治疗中断之间的关联。MAP.3试验是一个随机、安慰剂对照的依西美坦(一种芳香化酶抑制剂)疗

烤肉,熏肉增加乳腺癌幸存者的死亡风险

以前的研究已经将高烧烤或熏制肉的消费与增加的乳腺癌风险联系起来。现在,一项新的研究发现,它也可能增加患有该疾病的妇女的全因死亡率的风险。 北卡罗来纳大学教堂山的研究共同作者Humberto Parada及其同事最近在“国家癌症研究所杂志”上报道了他们的发现。 在皮肤癌后,乳腺癌是美国妇女中最常见的癌症。今年,估计在美国将诊断出约252,710例新的乳腺癌病例,超过40,000名妇女将死于

Nature:为什么内分泌疗法对某些乳腺癌患者无效

导语:来自瑞士巴塞尔大学的研究人员鉴定出肿瘤抑制基因LATS在乳腺癌发展和治疗中发挥着关键性的作用,解释了为何某些乳腺癌病人对常规疗法产生抵抗性。相关研究结果于2017年1月9日在线发表在Nature期刊上。乳腺癌为什么会进一步发展?为何某些乳腺癌病人对常规疗法产生抵抗性?来自瑞士巴塞尔大学的研究人员对乳腺组织中这些分子过程获得了新的认识。他们鉴定出肿瘤抑制基因LATS在乳腺癌发展和治疗中发挥着关

Nat Commun:华人科学家发现阻止乳腺癌转移的潜在药物

  最近一项研究发现,得到美国FDA审批通过的一类药物或可阻止乳腺癌转移。梅奥诊所的研究人员在研究中发现关键药物靶点CDK4/6能够调节一个参与癌症转移的蛋白SNAIL,抑制CDK4/6的药物可以阻止三阴性乳腺癌的转移。相关研究结果发表在国际学术期刊Nature Communications上。 CDK4/6抑制剂曾得到审批用于治疗雌激素阳性乳腺癌,但是否对三阴性乳腺癌有效并没

Baidu
map
Baidu
map
Baidu
map